

**2. Cancer (Condition after Cancer Surgery and Unspecified Adverse Drug Reactions of Anti-cancer Drugs)****Reference**

Katsuno H, Maeda K, Kaiho T, et al. Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902). *Japanese Journal of Clinical Oncology* 2015; 45: 650-6.

**1. Objectives**

To evaluate the efficacy of daikenchuto (大建中湯) for gastrointestinal dysfunction following colon surgery.

**2. Design**

Double-blind, randomized controlled trial (DB-RCT).

**3. Setting**

Fifty-one centers, including university hospitals.

**4. Participants**

Three hundred and eighty-six patients, colon cancer stage I-IIIb, T=1-3, N=0-2, M=0, who had colon resection by laparotomy.

**5. Intervention**

Among 386 patients, 354 were allocated.

Arm 1: TSUMURA Daikenchuto (大建中湯) Extract Granules (n=181) 15g/day (5g t.i.d.) administered orally from day 2 to day 8 after surgery.

Arm 2: Placebo granules (n=173) 15g/day (5g t.i.d.) administered orally for the same period as above.

Administration from day 2 to day 8 after surgery.

**6. Main outcome measures**

Time until first flatus after surgery, flatus frequency per day from day 2 to day 8 after surgery, stool shape, blood CRP level, patient QOL score using GSRS.

**7. Main results**

In arm 1, there were 7 dropouts (174 were analyzed), while in arm 2 there were 11 dropouts with 162 being analyzed. No significant difference was observed for time until first flatus after surgery, blood CRP level, or GSRS score. Flatus frequency per day from day 2 to day 8 after surgery was enhanced in the daikenchuto group from day 2 to 6, but decreased on days 7 and 8. Frequency of bowel movement was significantly lower compared to the placebo group on day 8 after surgery (P=0.024).

**8. Conclusion**

Drug efficacy is observed in daikenchuto for 1 week after surgery, but it is slow, and no clinical significance is observed for patients following laparotomy.

**9. From Kampo medicine perspective**

None.

**10. Safety assessment in the article**

7 adverse events of grade 3 or higher occurred among the trial subjects, but no significant difference between the groups was observed.

**11. Abstractor's comments**

No significant difference was found in time until flatus, stool shape, or QOL score by taking daikenchuto after laparotomy. Nevertheless, there was a strong flatus trend in the daikenchuto group up to day 6 after surgery, but the flatus trend was then found to reverse, decreasing on days 7 and 8. These results correspond to a sense of clinical usability, and it may be possible to elicit significant differences by increasing the number of participants and reexamining them. And in regard to the problem of when to end daikenchuto use started after surgery, this paper also suggests the possibility that it might be appropriate to divide the time after surgery into weeks.

**12. Abstractor and date**

Nakata H, 2 February 2017.